Literature DB >> 10338516

Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease.

L M Higgins1, G Frankel, G Douce, G Dougan, T T MacDonald.   

Abstract

Citrobacter rodentium is a classically noninvasive pathogen of mice that is similar to enteropathogenic Escherichia coli (EPEC) in man. Following oral infection of young mice, the organism colonizes the distal colon, and within 1 week the colonic mucosa doubles in thickness and there is massive epithelial cell hyperplasia. Since T-cell responses in mouse models of inflammatory bowel disease (IBD) also cause epithelial hyperplasia, we have investigated the possibility that C. rodentium promotes similar T-cell responses in the mucosa, thereby increasing epithelial shedding, transmission, and replication of the organism. Beginning 6 days after infection, bacteria were observed to be in close association with the epithelial surface and were also visible scattered throughout the lamina propria and in the submucosa. There was a CD3(+)-cell infiltrate into the colonic lamina propria and epithelium as well as mucosal thickening and crypt hyperplasia. The majority of CD3(+) cells were CD4(+) and were not gammadelta+. Reverse transcription-PCR analysis of cytokines also revealed a highly polarized Th1 response (interleukin-12, gamma interferon, and tumor necrosis factor alpha) in the mucosa and a large increase in the epithelial cell mitogen keratinocyte growth factor. None of the changes were seen in mice inoculated with bacteria lacking intimin (which is necessary for colonization), but they were seen in mice inoculated with C. rodentium complemented with intimin from EPEC. This is the first example of a classically noninvasive bacterial pathogen which elicits a strong mucosal Th1 response and which produces pathology similar to that seen in mouse models of IBD, which is also characterized by a strong Th1 response. These results also suggest that the colonic mucosa responds in a stereotypic way to Th1 responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10338516      PMCID: PMC96617          DOI: 10.1128/IAI.67.6.3031-3039.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Characterization of the mucosal cell-mediated immune response in IL-2 knockout mice before and after the onset of colitis.

Authors:  S A McDonald; M J Palmen; E P Van Rees; T T MacDonald
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

2.  A third secreted protein that is encoded by the enteropathogenic Escherichia coli pathogenicity island is required for transduction of signals and for attaching and effacing activities in host cells.

Authors:  L C Lai; L A Wainwright; K D Stone; M S Donnenberg
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

3.  CD4+ T-cell population mediates development of inflammatory bowel disease in T-cell receptor alpha chain-deficient mice.

Authors:  I Takahashi; H Kiyono; S Hamada
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

4.  Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during Crohn's disease surgery.

Authors:  N S Ambrose; M Johnson; D W Burdon; M R Keighley
Journal:  Br J Surg       Date:  1984-08       Impact factor: 6.939

5.  Peyer's patch adherence of enteropathogenic Escherichia coli strains in rabbits.

Authors:  L K Von Moll; J R Cantey
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

6.  Keratinocyte growth factor in inflammatory bowel disease. Increased mRNA transcripts in ulcerative colitis compared with Crohn's disease in biopsies and isolated mucosal myofibroblasts.

Authors:  M Bajaj-Elliott; E Breese; R Poulsom; P D Fairclough; T T MacDonald
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

7.  Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease.

Authors:  M Brauchle; M Madlener; A D Wagner; K Angermeyer; U Lauer; P H Hofschneider; M Gregor; S Werner
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

8.  The cell-binding domain of intimin from enteropathogenic Escherichia coli binds to beta1 integrins.

Authors:  G Frankel; O Lider; R Hershkoviz; A P Mould; S G Kachalsky; D C Candy; L Cahalon; M J Humphries; G Dougan
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

9.  Intimin from enteropathogenic Escherichia coli restores murine virulence to a Citrobacter rodentium eaeA mutant: induction of an immunoglobulin A response to intimin and EspB.

Authors:  G Frankel; A D Phillips; M Novakova; H Field; D C Candy; D B Schauer; G Douce; G Dougan
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

10.  Transmissible murine colonic hyperplasia.

Authors:  S W Barthold; G L Coleman; R O Jacoby; E M Livestone; A M Jonas
Journal:  Vet Pathol       Date:  1978-03       Impact factor: 2.221

View more
  119 in total

1.  Binding of intimin from enteropathogenic Escherichia coli to lymphocytes and its functional consequences.

Authors:  Nathalie S Gonçalves; Christine Hale; Gordon Dougan; Gad Frankel; Thomas T MacDonald
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 2.  The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities.

Authors:  Zhi Huang; Aaron H Rose; Peter R Hoffmann
Journal:  Antioxid Redox Signal       Date:  2012-01-09       Impact factor: 8.401

3.  Concurrent infection with an intestinal helminth parasite impairs host resistance to enteric Citrobacter rodentium and enhances Citrobacter-induced colitis in mice.

Authors:  Chien-Chang Chen; Steve Louie; Beth McCormick; W Allan Walker; Hai Ning Shi
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  CEACAM1 regulates CD8+ T cell immunity and protects from severe pathology during Citrobacter rodentium induced colitis.

Authors:  Julia Zöller; Jana-Fabienne Ebel; Vishal Khairnar; Verena Schmitt; Robert Klopfleisch; Jana Meiners; Virginia Seiffart; Wiebke Hansen; Jan Buer; Bernhard B Singer; Karl S Lang; Astrid M Westendorf
Journal:  Gut Microbes       Date:  2020-06-10

5.  Polyethylene glycol diminishes pathological effects of Citrobacter rodentium infection by blocking bacterial attachment to the colonic epithelia.

Authors:  Wentao Qi; Suhasini Joshi; Christopher R Weber; Ramesh K Wali; Hemant K Roy; Suzana D Savkovic
Journal:  Gut Microbes       Date:  2011-09-01

6.  Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium.

Authors:  Sarah L Lebeis; Kimberly R Powell; Didier Merlin; Melanie A Sherman; Daniel Kalman
Journal:  Infect Immun       Date:  2008-12-15       Impact factor: 3.441

7.  Streptococcus pneumoniae-induced pneumonia and Citrobacter rodentium-induced gut infection differentially alter vitamin A concentrations in the lung and liver of mice.

Authors:  Katherine H Restori; Kaitlin L McDaniel; Amanda E Wray; Margherita T Cantorna; A Catharine Ross
Journal:  J Nutr       Date:  2014-01-15       Impact factor: 4.798

8.  Alternatively activated macrophages in intestinal helminth infection: effects on concurrent bacterial colitis.

Authors:  Meiqian Weng; Deke Huntley; I-Fei Huang; Ondulla Foye-Jackson; Lijian Wang; Aliese Sarkissian; Qingping Zhou; W Allan Walker; Bobby J Cherayil; Hai Ning Shi
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

9.  Modulation of intestinal goblet cell function during infection by an attaching and effacing bacterial pathogen.

Authors:  Kirk S B Bergstrom; Julian A Guttman; Mohammad Rumi; Caixia Ma; Saied Bouzari; Mohammed A Khan; Deanna L Gibson; A Wayne Vogl; Bruce A Vallance
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

10.  Development of fatal colitis in FVB mice infected with Citrobacter rodentium.

Authors:  Diana Borenshtein; Prashant R Nambiar; Elizabeth B Groff; James G Fox; David B Schauer
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.